© 2023 BioMarin. All rights reserved.

Completed Studies



Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)

  • Indication

    Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome)

  • Investigational Therapeutic

    Naglazyme® (galsulfase)

  • Study Type

    Phase 4

  • Goal

    The objectives of this program are: to further characterize the natural progression of MPS VI disease; to generate and disseminate information on the care and management of MPS VI patients to clinical and medical professionals; to provide a resource to physicians and patients by providing information for optimizing patient care based on aggregate data; to characterize the clinical response to long-term Naglazyme® (galsulfase) treatment; to further characterize the long-term safety of Naglazyme® treatment.

  • Status

    This study has been completed

Visit Study MPSVI CSP Now